May 19th 2025
The FDA previously approved Jivi in 2018 to treat adults aged 12 years and older with hemophilia A.
Addressing the Gaps and Clinical Challenges in Chronic Lymphocytic Leukemia: Updates and Strategies for Managed Care
The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation
ASH Annual Meeting Coverage: Highlighting the Recent Updates in TKI Use in the Treatment of CML – Insights and Application for Managed Care
Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care
Overcoming Operational and Clinical Barriers in Multiple Myeloma: Managed Care Strategies for Antibody-Based Regimens
Exploring Therapeutic Advances in Myelofibrosis and Key Considerations for Effective Management
NSAIDs May Be Safe for Use in Hemophilia, but More Research Is Needed